Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts’ over future operations
Published
Here are U.S. stocks in focus ahead of Wednesday’s trading session: Reata Pharmaceuticals’ RETA stock shot up more than 177% on Wednesday morning after the Food and Drug administration approved a drug treatment for a disease called Friedreich’s ataxia, a rare inherited disease that causes damage…
#reatapharmaceuticals #foodanddrug